Amplyx Pharmaceuticals
Edit

Amplyx Pharmaceuticals

https://amplyx.com/
Last activity: 06.07.2021
Probably Closed
Categories: CauseDrugFinTechHealthTechInvestmentITLifeManagementProductResearch
Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions.

For more information on Amplyx, please visit our website at www.amplyx.com
Followers
169
Followers
1.97K
Mentions
23
Location: United States, California, San Diego
Employees: 11-50
Total raised: $207.7M

Investors 8

Funding Rounds 5

DateSeriesAmountInvestors
20.05.2020Series C$90MSofinnova ...
02.08.2017Series C$67MNew Enterp...
09.02.2016-$8.7M-
11.11.2015Series B$40.5M-
09.04.2010-$1.5M-

Mentions in press and media 23

DateTitleDescription
03.12.2020Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting
06.11.2020Covid-19 roundup: No­var­tis treat­ment comes up short in PhI­II; Hu­mani­gen ex­pands tri­al, but draws crit­i­cismA ma­jor play­er try­ing to adapt an an­ti-in­flam­ma­to­ry for Covid-19 has seen the drug fall flat. No­var­tis re­port­ed Fri­day that a Phase III tri­al eval­u­at­ing canakinum­ab in hos­pi­tal­ized Covid-19 cas­es with pneu­mo­nia and c...
20.05.2020Amplyx closes $53 million Series C extension-
19.05.2020Amplyx Pharmaceuticals Closes $53M Series C ExtensionAmplyx Pharmaceuticals, a San Diego, CA-based biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, closed a $53m Series C extension, which brings the Ser...
19.05.2020Immune Therapeutics Company Amplyx Pharmaceuticals Adds $53M in a Series C Extension-
19.05.2020 Amplyx Pharmaceuticals Adds $53M In Funding San Diego-based Amplyx Pharmaceuticals has raised $53M in a Series C extension funding, bringing its Series C funding to over $90M, the comapny announced this morning. Amplyx--which is developing therapeutics for treating patients with comp...
17.09.2019Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine→ Am­gen has en­list­ed Hum­ming­bird Bio­science on a new an­ti­body dis­cov­ery pact, turn­ing over some nov­el tar­gets to see if the small­er play­er’s “sys­tems bi­ol­o­gy” plat­form can yield bet­ter ther­a­peu­tics. Start­ing with tw...
03.08.2017Term Sheet — Thursday, Aug. 3MARKDOWNS AGAIN After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns. Paid Content What you need to know about growing cyberattacks From ExtraHop • This i...
02.08.2017NEA Joins $67M Series C for Amplyx PharmaceuticalsAmplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other n...
02.08.2017Amplyx Pharmaceuticals Raises $67m in Series C FinancingAmplyx Pharmaceuticals, a San Diego, CA-based company developing novel antifungal agents for life-threatening fungal infections, raised $67m in Series C financing. The round was led by Sofinnova Venture Partners with participation from othe...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In